Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP

• Status: Unknown status
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to identify the incidence of hepatitis B virus reactivation rate in Diffuse Large B Cell or high grade Follicular lymphoma patients with prior resolved hepatitis B undergoing RCHOP immuno-chemotherapy.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Lamivudine; Reverse Transcriptase Inhibitors

Criteria

Inclusion Criteria:

• Naive DLBCL or high grade FL patients

• Age range 18-75 years old

• ECOG performance status 0-3

• Life expectancy of more than 3 months

• Adequate organ function

• HBsAg negative/HBcAb positive at baseline

Exclusion Criteria:

• Infection of HAV,HCV,HIV

• Pregnant or lactating women

• Serious uncontrolled diseases